parallel randomized trial

S003015

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Type 2 diabetes (adults)S003015

Design

Randomized: 92
Start year: 2016
Treatment: 12 weeks, follow-up 12 weeks
Countries: China (1 sites)
Sponsor: (not reported)
Eligibility: T2D; not on oral glucose lowering drugs or insulin; no heart, kidney or liver damage

Conduct and analysis

Blinding: not reported
Sequence generation: not reported
Allocation concealment: not reported
Outcome adjudication: not reported
Primary estimand: not stated
Analysis population
Missing data

Arms

Arm	Treatment	Background	Randomized	Analyzed	Completed treatment
A1	Standard care or no added treatment Control, insulin aspart 30 alone	insulin aspart 30 0.3 to 0.5 U/kg/day before breakfast and dinner; diet and exercise; lifestyle: standard	46	46
A2	liraglutide Observation, liraglutide plus insulin aspart 30	insulin aspart 30 0.3 to 0.5 U/kg/day before breakfast and dinner; diet and exercise; lifestyle: standard	46	46

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.

Characteristic	Statistic	Whole trial ALL
age	max (years)	65
age	mean (years)	56.37
age	min (years)	30
age	sd (years)	4.15
diabetes duration	max (years)	16
diabetes duration	mean (years)	9.85
diabetes duration	min (years)	1
diabetes duration	sd (years)	1.34
female	n	42
female	percent	45.65